OXACELL® AG was established in 2009 in Potsdam, Germany. In 2014, our long-lasting research efforts in the field of human stem cells was rewarded with the GMP-certification of the manufacturing process for Oxacells HP (high purity), a concentrated stem cell product for the treatment of osteoarthritis in various joints. Since then, we focus on the provision and advancement of personalized medicinal products based on adipose-derived stem cells. Our newest platform technology is Oxacells CULT, cultivated stem cells intended for the allogenic treatment of e.g. liver disease.